Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Malignant Mesothelioma: Time To Translate?

A. Napolitano, M. Carbone
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Malignant mesothelioma is an aggressive cancer largely associated with asbestos exposure. In this review, we will discuss the significant advancements in our understanding of its genetics and molecular biology and their translational relevance. Remarkable findings included the discovery of germline and somatic mutations of BRCA1 associated protein-1 (BAP1) in patients, and the genome-wide characterization of pathways altered in mesothelioma that could be potentially exploited to design novel therapeutic approaches. Nevertheless, the clinical translation of these molecular findings has been slow and insufficient. In order to rapidly move translation from the bench to the bedside, we believe that cooperative research efforts have to be further endorsed and promoted at all levels.
This paper references
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.1586/17476348.2015.1081066
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies
A. Bononi (2015)
10.1111/cas.12687
Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study
J. Xu (2015)
10.3816/CLC.2003.N.031
Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40.
A. Gazdar (2003)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
10.18632/oncotarget.7229
Targeting hypoxic response for cancer therapy
E. Paolicchi (2016)
10.1016/j.lungcan.2012.03.024
Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure.
A. Rostila (2012)
10.1073/pnas.1110013108
Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis
H. Nagai (2011)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1097/JTO.0000000000000436
Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study
M. Lo Iacono (2015)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.1158/1078-0432.CCR-11-2259
Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma
M. Carbone (2011)
10.1186/s12014-016-9103-3
ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
D. Morré (2016)
10.1158/1541-7786.MCR-13-0111
A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Megan N Farley (2013)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
10.1038/sj.onc.1209587
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK
P. Poulikakos (2006)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1038/onc.2015.243
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano (2016)
10.1158/0008-5472.CAN-15-3371
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Yuwaraj Kadariya (2016)
10.1016/j.mrgentox.2008.06.011
Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.
M. Amati (2008)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
10.1016/j.ccr.2014.05.001
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
W. Li (2014)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1016/j.ajhg.2013.04.012
Germline BAP1 mutations predispose to renal cell carcinomas.
Tatiana Popova (2013)
10.1038/ng.910
Germline mutations in BAP1 predispose to melanocytic tumors
T. Wiesner (2011)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1016/j.gene.2015.03.031
Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
S. Sneddon (2015)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1038/nrc3459
BAP1 and cancer
M. Carbone (2013)
10.1038/onc.2015.125
Role of Merlin/NF2 Inactivation in Tumor Biology
A. Petrilli (2016)
10.1038/nrd3375
Trial watch: Phase III and submission failures: 2007–2010
John Arrowsmith (2011)
10.1038/nature08966
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
Johanna C. Scheuermann (2010)
10.1371/journal.pgen.1005633
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
M. Carbone (2015)
Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.
G. Ugurluer (2016)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1016/S1383-5718(00)00053-X
Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany.
B. Marczynski (2000)
10.1179/2049396712Y.0000000016
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
S. Jane Henley (2013)
10.1136/oem.49.8.566
The mortality of amphibole miners in South Africa, 1946-80.
G. K. Sluis‐Cremer (1992)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
Simian virus 40: the link with human malignant mesothelioma is well established.
M. Carbone (2000)
10.1186/1479-5876-10-179
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
M. Carbone (2012)
10.1038/cddis.2015.153
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression
H. Yang (2015)
10.1371/journal.pone.0104848
Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
M. Comar (2014)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.
H. Lin (2014)
10.1111/cge.12472
Germline BAP1 mutations predispose also to multiple basal cell carcinomas
A. de la Fouchardière (2015)
10.1186/s12967-014-0301-3
Evaluation of clonal origin of malignant mesothelioma
Sabahattin Comertpay (2014)
10.1016/S1470-2045(13)70257-2
Asbestos is not just asbestos: an unrecognised health hazard.
F. Baumann (2013)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1158/1078-0432.CCR-13-2429
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
A. de Reyniès (2014)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/j.lungcan.2014.10.017
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Andreas Rusch (2015)
10.1128/MCB.01578-08
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
M. López-Lago (2009)
10.1080/21645515.2015.1050572
Preclinical development of HIvax: Human survivin highly immunogenic vaccines
P. Hoffmann (2015)
10.1136/thoraxjnl-2014-206464
Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies
K. Blyth (2014)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1111/j.1349-7006.2012.02223.x
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
10.1038/cgt.2010.10
Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
H. Li (2010)
10.1016/j.molonc.2014.08.005
The p53/mouse double minute 2 homolog complex deregulation in merlin‐deficient tumours
S. Ammoun (2015)
10.1593/NEO.08642
The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Katherine Striedinger (2008)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1111/cge.12501
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
K.A.W. Wadt (2015)
10.18632/ONCOTARGET.3765
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors
J. Sacco (2015)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar